Biological Safety Testing Market size is valued at USD 3,520.0 million in 2021 and is expected to reach a value of USD 8,541.5 million by 2028, growing at a CAGR of 13.5% during the forecast period 2022 to 2028. The global market provides a detailed overview of the biological safety testing market and that can be segmented by product type, application type, and test type. By product type, the biological safety testing market has been segmented into kits and reagents, services, and instruments. The kits and reagents segment is likely to be the largest and fastest-growing segment in terms of product type. Based on test type, the biological safety testing market is segmented into endotoxin tests, sterility tests, cell line authentication and characterization tests, bioburden tests, residual host contaminant detection tests, adventitious agent detection tests, and other tests. Among these, the bioburden tests segment is expected to have the fastest-growing market during the forecast period 2022-2028. On the basis of application, the market is segregated into vaccine & therapeutics development, blood and blood-related product testing, cellular and gene therapy, tissue and tissue-related product testing, and stem cell research. Vaccine & therapeutics development is likely to be the fastest-growing segment in the market.
In 2021, EndoScan-V, a verified endotoxin detection and measurement software used to generate and report quantitative test data, has been released by Charles River Laboratories, Inc. (US). The software took the necessary measurements and calculations and generated test results, which could be approved with a digital signature.